A deep dive into newborns’ DNA may reveal potential disease risks — but is the testing worth it?
Looking for diseases in newborns’ DNA that could arise during adulthood is more ethically fraught than focusing on childhood conditions.
3 global health challenges to watch in 2019
Will the U.S. get a licensed dengue vaccine? Will Sanofi pocket a coveted prize?…
Opinion: ‘Passive’ fentanyl exposure: more myth than reality
Reports that merely being in a room with fentanyl, a powerful opioid, or its analogues can poison you don't match the action and effects of these drugs.
Flu vaccinations rise sharply in both children and adults
The increase in early vaccination may be due to fresh memories of how bad last winter was, but other factors may also be at play.
A Kentucky appeals court sided with STAT, upholding a ruling ordering the release of Purdue Pharma records about the marketing of the opioid OxyContin.
The apparent birth this month of the first genetically modified babies is “a lesson in the potential for human hubris to overtake us,” Dr. Francis Collins, the director of the National Institutes of Health.
The Department of Health and Human Services asserted in a letter to the Drug Enforcement Administration that two chemicals in kratom should be classified as Schedule I substances, meaning that the chemicals have “a high potential for abuse” and that…
A new study examining how long black or white people survive after a heart attack concludes that it’s socioeconomic status, far more than race, that explains who fares better.
If Republicans prevail in just two races on Tuesday, the Senate’s ranks would suddenly include two former drug industry lobbyists and a pharma CEO.
